Neoleukin Therapeutics, Inc.
Hedge Funds Holdings
Last updated:
Neoleukin Therapeutics, Inc.‘s stocks are currently a part of 18 hedge funds’ portfolios, which represents 5.43% of the total amount of its stocks outstanding. This makes up a total of 2.99M shares of Neoleukin Therapeutics, Inc.. Compared to the previous quarter, the number fell by -82.40% or -14.03M shares fewer. As for the holding position changes, 16.67% (3) of current hedge fund investors increased the number of shares held, 38.89% (7) of current holders sold a part of the shares held, and 44.44% (8) closed the holdings completely. 2 hedge funds are new holders of Neoleukin Therapeutics, Inc. stock in Q1 2023, it is 11.11% of total holders.
Hedge funds holding Neoleukin Therapeutics (Q3 2019 – Q1 2023)
| Q3 2019 | 35 |
|---|---|
| Q4 2019 | 55 |
| Q1 2020 | 60 |
| Q2 2020 | 73 |
| Q3 2020 | 80 |
| Q4 2020 | 84 |
| Q1 2021 | 81 |
| Q2 2021 | 82 |
| Q3 2021 | 82 |
| Q4 2021 | 77 |
| Q1 2022 | 78 |
| Q2 2022 | 55 |
| Q3 2022 | 48 |
| Q4 2022 | 46 |
| Q1 2023 | 18 |
Hedge funds changes in Neoleukin Therapeutics positions (Q3 2019 – Q1 2023)
| Q3 2019 | 35 | 0 | 0 | 0 | 0 |
|---|---|---|---|---|---|
| Q4 2019 | 29 | 9 | 13 | 9 | -5 |
| Q1 2020 | 17 | 19 | 12 | 12 | 0 |
| Q2 2020 | 26 | 27 | 12 | 13 | -5 |
| Q3 2020 | 21 | 33 | 13 | 13 | 0 |
| Q4 2020 | 19 | 28 | 22 | 15 | 0 |
| Q1 2021 | 5 | 23 | 33 | 8 | 12 |
| Q2 2021 | 10 | 27 | 24 | 9 | 12 |
| Q3 2021 | 9 | 26 | 28 | 8 | 11 |
| Q4 2021 | 14 | 24 | 26 | 19 | -6 |
| Q1 2022 | 14 | 25 | 26 | 13 | 0 |
| Q2 2022 | 11 | 15 | 19 | 32 | -22 |
| Q3 2022 | 4 | 6 | 18 | 11 | 9 |
| Q4 2022 | 8 | 7 | 15 | 8 | 8 |
| Q1 2023 | 2 | 3 | 7 | 8 | -2 |
Hedge funds changes in Neoleukin Therapeutics stock options (Q3 2019 – Q1 2023)
| Q3 2019 | 1,000 | 0 |
|---|---|---|
| Q4 2019 | 777,000 | 632,000 |
| Q1 2020 | 815,000 | 183,000 |
| Q2 2020 | 387,000 | 564,000 |
| Q3 2020 | 156,000 | 367,000 |
| Q4 2020 | 1,237,000 | 2,565,000 |
| Q1 2021 | 1,001,000 | 2,699,000 |
| Q2 2021 | 703,000 | 1,967,000 |
| Q3 2021 | 287,000 | 87,000 |
| Q4 2021 | 1,280,000 | 180,000 |
| Q1 2022 | 337,000 | 246,000 |
| Q2 2022 | 141,000 | 0 |
| Q3 2022 | 0 | 0 |
| Q4 2022 | 0 | 0 |
| Q1 2023 | 0 | 0 |